NSAID, Antihistamine Use More Affected By Copay Raise Than Other Rxs – Study
This article was originally published in The Tan Sheet
Consumer spending on prescription non-steroidal anti-inflammatories and antihistamines decreased 45% and 44%, respectively, when insurance copays for the products doubled, according to a study published in the Journal of the American Medical Association May 19
You may also be interested in...
Domestic sales of Johnson & Johnson's Rx proton pump inhibitor Aciphex (rabeprazole 20 mg) were negatively affected by the launch of Procter & Gamble's Prilosec OTC, providing another example of the sluggish growth of the prescription PPI market
Aventis is considering outlicensing the antihistamine Allegra (fexofenadine) as a "contingency plan" in the event that the product loses its sole-source prescription-only status
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC